.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Chubb
Citi
UBS
Covington
Deloitte
Merck
Farmers Insurance
Johnson and Johnson
McKinsey

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title: Antiviral 1,3-dioxolane nucleoside analogues
Abstract:This invention includes the compounds 2'-deoxy-5-fluoro-3'-oxacytidine, (-)-2'-deoxy-5-fluoro-3'-oxacytidine, and (+)-2'-deoxy-5-fluoro-3+-oxacytidine, and pharmaceutically acceptable salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection.
Inventor(s): Liotta; Dennis C. (McDonough, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)
Assignee: Emory University (Atlanta, GA)
Filing Date:Nov 09, 1993
Application Number:08/150,012
Claims:1. (.+-.)-2'-Deoxy-5-fluoro-3'-oxacytidine.

2. (-)-.beta.-2'-Deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer.

3. (+)-.beta.-2'-Deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer.

4. A pharmaceutical composition that comprises 2'-deoxy-5-fluoro-3'-oxacytidine, its (-) or (+) enantiomer or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

5. A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of .beta.-2'-deoxy-5-fluoro-3'-oxacytidine or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.

6. A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of (+)-.beta.-2'-deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.

7. A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of (-)-.beta.-2'-deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Julphar
Harvard Business School
Baxter
Johnson and Johnson
Medtronic
AstraZeneca
Novartis
Queensland Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot